Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Braden Michael Leonard10% Owner | Aclaris TherapeuticsACRS | Open-market sale | 04/23 | 04/27 | 300,000 sh | $4.53 | $1,359,000 | −2.1% |
Anand MehraDirector | Aclaris TherapeuticsACRS | Open-market buy | 24/11/19 | 24/11/20 | 666,666 sh | $2.25 | $1,499,998.5 | +1537.4% |
Aclaris TherapeuticsACRS | Open-market buy | 24/08/02–24/08/05 | 24/08/05 | 373,569 sh2 trades | $1.26avg. | $471,602.76 | +2.7% | |
Aclaris TherapeuticsACRS | Open-market buy | 24/07/30–24/07/31 | 24/07/31 | 273,730 sh2 trades | $1.31avg. | $358,849 | +2.0% | |
Aclaris TherapeuticsACRS | Open-market buy | 24/07/18–24/07/22 | 24/07/22 | 154,722 sh3 trades | $1.30avg. | $201,670.08 | +1.2% | |
Aclaris TherapeuticsACRS | Open-market buy | 24/07/02–24/07/05 | 24/07/05 | 352,397 sh3 trades | $1.15avg. | $405,828.51 | +2.7% | |
Aclaris TherapeuticsACRS | Open-market buy | 24/06/27–24/07/01 | 24/07/01 | 1,543,434 sh4 trades | $1.13avg. | $1,741,844.76 | +13.4% | |
Aclaris TherapeuticsACRS | Open-market buy | 24/06/14–24/06/18 | 24/06/18 | 545,000 sh3 trades | $1.16avg. | $629,650 | +5.0% | |
Aclaris TherapeuticsACRS | Open-market buy | 24/06/11–24/06/13 | 24/06/13 | 1,611,200 sh4 trades | $1.11avg. | $1,781,768 | +17.1% | |
Aclaris TherapeuticsACRS | Open-market buy | 24/03/01–24/03/04 | 24/03/05 | 14,500 sh2 trades | $1.24avg. | $17,955 | +101.0% | |
Joseph MonahanChief Scientific Officer | Aclaris TherapeuticsACRS | Open-market sale10b5-1 plan | 23/10/23 | 23/10/25 | 6,000 sh | $5.08 | $30,480 | −4.4% |
Aclaris TherapeuticsACRS | Open-market buy | 23/09/06 | 23/09/07 | 9,490 sh | $7.90 | $74,971 | +158.9% | |
James LoeropChief Business Officer | Aclaris TherapeuticsACRS | Open-market buy | 23/08/28 | 23/08/28 | 14,705 sh | $6.80 | $99,994 | +210.6% |
Joseph MonahanChief Scientific Officer | Aclaris TherapeuticsACRS | Open-market sale10b5-1 plan | 23/08/21 | 23/08/22 | 6,000 sh | $7.32 | $43,920 | −4.2% |
Joseph MonahanChief Scientific Officer | Aclaris TherapeuticsACRS | Open-market sale10b5-1 plan | 23/06/20 | 23/06/22 | 6,000 sh | $10.28 | $61,680 | −4.1% |
Douglas J. ManionPres and CEO | Aclaris TherapeuticsACRS | Open-market buy | 23/03/17 | 23/03/17 | 6,300 sh | $7.86 | $49,518 | +96.9% |
Douglas J. ManionPres and CEO | Aclaris TherapeuticsACRS | Open-market buy | 23/03/09 | 23/03/09 | 6,500 sh | $7.74 | $50,310 | No record |
Aclaris TherapeuticsACRS | Open-market sale | 23/03/02–23/03/03 | 23/03/03 | 59,240 sh2 trades | $12.50avg. | $740,661.2 | −4.4% | |
Aclaris TherapeuticsACRS | Open-market sale | 23/03/02–23/03/03 | 23/03/03 | 30,837 sh2 trades | $12.51avg. | $385,623.31 | −17.3% | |
Aclaris TherapeuticsACRS | Open-market sale | 23/03/02–23/03/03 | 23/03/03 | 1,894 sh2 trades | $12.45avg. | $23,581.22 | −26.5% |